congo red has been researched along with Cognition Disorders in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Gruys, E; Rofina, JE; Secrève, M; Toussaint, MJ; van der Meer, I; van der Spek, A; van Ederen, AM; Van Eerdenburg, FJ | 1 |
Morton, AJ; Pallier, PN; Wanderer, J; Wood, NI | 1 |
2 other study(ies) available for congo red and Cognition Disorders
Article | Year |
---|---|
Cognitive disturbances in old dogs suffering from the canine counterpart of Alzheimer's disease.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Age Factors; Aging; Aldehydes; Alzheimer Disease; Amyloid beta-Peptides; Animals; Atrophy; Behavior, Animal; Cerebral Cortex; Cognition Disorders; Congo Red; Demyelinating Diseases; Deoxyguanosine; Disease Models, Animal; Dogs; Female; Immunohistochemistry; Lipofuscin; Male; Statistics, Nonparametric | 2006 |
Systemic administration of Congo red does not improve motor or cognitive function in R6/2 mice.
Topics: Animals; Blood-Brain Barrier; Body Weight; Brain; Cognition; Cognition Disorders; Congo Red; Dyskinesias; Female; Humans; Huntington Disease; Inclusion Bodies; Locomotion; Male; Maze Learning; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Transgenic; Neurons; Neuroprotective Agents; Recovery of Function; Treatment Failure | 2007 |